166 related articles for article (PubMed ID: 1417016)
21. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
22. A comparative study of four serological tumor markers for the detection of breast cancer.
Clinton SR; Beason KL; Bryant S; Johnson JT; Jackson M; Wilson C; Holifield K; Vincent C; Hall M
Biomed Sci Instrum; 2003; 39():408-14. PubMed ID: 12724928
[TBL] [Abstract][Full Text] [Related]
23. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
[TBL] [Abstract][Full Text] [Related]
24. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3.
Jacobs IJ; Oram DH; Bast RC
Obstet Gynecol; 1992 Sep; 80(3 Pt 1):396-9. PubMed ID: 1495694
[TBL] [Abstract][Full Text] [Related]
25. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer].
Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018
[TBL] [Abstract][Full Text] [Related]
26. [Relationship between tumor markers and clinical symptoms in ovarian cancer].
Yakushiji M; Nishimura H
Rinsho Byori; 1992 Apr; 40(4):354-8. PubMed ID: 1593760
[TBL] [Abstract][Full Text] [Related]
27. [Comparison of 3 assay kits of prostate specific antigen in serum of prostatic cancer].
Akimoto S; Akakura K; Shimazaki J
Hinyokika Kiyo; 1988 Dec; 34(12):2143-8. PubMed ID: 2467543
[TBL] [Abstract][Full Text] [Related]
28. [The CA-125 tumor marker in epithelial ovarian cancers of stage I].
Nagele F; Vavra N; Kurz C; Sevelda P
Wien Klin Wochenschr; 1993; 105(20):585-8. PubMed ID: 8259686
[TBL] [Abstract][Full Text] [Related]
29. [Basic and clinical evaluation of an immunoradiometric competitive inhibition assay for sialyl Tn antigen: (1). Evaluation of assay conditions and normal values. STN Study Group].
Imura H; Mori T; Ohkura H; Ishii M; Ariyoshi H; Endo J; Kitao M; Takeda I; Kobayashi H; Inoue M
Gan To Kagaku Ryoho; 1989 Sep; 16(9):3213-9. PubMed ID: 2782915
[TBL] [Abstract][Full Text] [Related]
30. [Preparation and evaluation of a time-resolved fluoroimmunoassay kit for CA50 determination].
Hang JF; Wu YS; Xu WW; Yu WH; Huang Y; Li M
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):189-92. PubMed ID: 17649634
[TBL] [Abstract][Full Text] [Related]
31. [Application of monoclonal antibody OC 125 in gynecological oncology].
Wu AR; Wang EY; Wang XX; Jia XH; Li L
Zhonghua Zhong Liu Za Zhi; 1988 Mar; 10(2):132-6. PubMed ID: 3208653
[TBL] [Abstract][Full Text] [Related]
32. [The evaluation of CA54/61 in the diagnosis of ovarian cancer--with special reference to the cooperative results of 5 institutes].
Nozawa S; Yajima M; Udagawa Y; Kiguchi K; Iizuka R; Kimura E; Terashima Y; Inaba N; Takamizawa H; Negishi Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Nov; 41(11):1823-9. PubMed ID: 2687409
[TBL] [Abstract][Full Text] [Related]
33. [Evaluation of CA 19-9 radioimmunoassay].
Toya D; Takemori Y; Kidani H; Yoneshima M; Hattori N; Sawabu N
Gan To Kagaku Ryoho; 1984 Mar; 11(3):509-14. PubMed ID: 6584087
[TBL] [Abstract][Full Text] [Related]
34. [Significance of CA 125 antigen levels in patients with ovarian cancer].
Shimizu Y; Fujiwara H; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Okudaira Y
Gan To Kagaku Ryoho; 1986 Jan; 13(1):46-52. PubMed ID: 3455806
[TBL] [Abstract][Full Text] [Related]
35. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer.
Suzuki M; Ohwada M; Aida I; Tamada T; Hanamura T; Nagatomo M
Obstet Gynecol; 1993 Dec; 82(6):946-50. PubMed ID: 8233270
[TBL] [Abstract][Full Text] [Related]
36. [Predictive value of the tumor marker combination CA-125 and beta-2-microglobulin in ovarian cancer].
Hernádi Z; Molnár V; Juhász B; Pólka R; Margitai B
Zentralbl Gynakol; 1992; 114(1):6-9. PubMed ID: 1585745
[TBL] [Abstract][Full Text] [Related]
37. Clinical evaluation of serum tumour markers CEA, CA 50 and CA 242 in colorectal cancer.
Eskelinen M; Pasanen P; Kulju A; Janatuinen E; Miettinen P; Poikolainen E; Tarvainen R; Nuutinen P; Pääkkönen M; Alhava E
Anticancer Res; 1994; 14(3B):1427-32. PubMed ID: 8067718
[TBL] [Abstract][Full Text] [Related]
38. [Clinical evaluation of TPA-assay kit using monoclonal antibodies].
Saga T; Sakahara H; Kousaka T; Yao Z; Nakamoto Y; Hattori N; Zhang M; Nakayama M; Ohshio G; Imamura M; Konishi J
Gan To Kagaku Ryoho; 1996 Apr; 23(5):615-21. PubMed ID: 8678521
[TBL] [Abstract][Full Text] [Related]
39. Immunoassay of CEA, CA 19-9, CA 125, and CA 15-3 on the automated systems ES 300 and ES 600: methodological evaluation from a multicentre collaborative study.
Zucchelli GC; Pilo A; Jaworek D; Masini S; Chiesa MR
Eur J Clin Chem Clin Biochem; 1992 Dec; 30(12):875-9. PubMed ID: 1489864
[TBL] [Abstract][Full Text] [Related]
40. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]